Previous 10 | Next 10 |
David Einhorn's 13F stock portfolio value increased from $1.22B to $1.66B this quarter. Greenlight increased Atlas Air Worldwide, Teck Resources, and Resideo Technologies while reducing AerCap Holdings, Chemours, and NCR Corp. during the quarter. The largest three positions are at...
Noting that the shares of Intercept Pharmaceuticals ([[ICPT]] +1.0%) have shed about ~30.0% of its value since its recent downgrade in late February, H.C. Wainwright has upgraded the stock to neutral from sell.Given an unchanged view in the underlying thesis, the analyst Ed Arce has however s...
Intercept Pharmaceuticals (ICPT) has announced that Sandip Kapadia, Chief Financial Officer will leave the company to pursue another opportunity.Mr. Kapadia will continue to serve in his position until March 26, 2021, the company said, adding that Rocco Venezia who will be appointed Chie...
Rocco Venezia Appointed Chief Accounting Officer and Acting CFO - Intercept Reiterates 2021 Financial Guidance - NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercializa...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Intercept Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
Intercept Pharmaceuticals, Inc. (ICPT) Q4 2020 Earnings Conference Call February 25, 2021 08:30 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Affairs Jerry Durso - President and CEO Sandip Kapadia - Chief Financial Officer Gail Cawkwell ...
Image source: The Motley Fool. Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Q4 2020 Earnings Call Feb 25, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Intercept Pharmaceuticals Inc (ICPT) Q4 2020 Earnings Call Tr...
Shares of Intercept Pharmaceuticals (ICPT) are down 6.2% to $26.84 in morning trading following the release of Q4 2020 results that missed on both EPS and revenue.Revenue in Q4 was $83.3M compared to $71.5M in the year-ago period, a 16.5% increase.Year-over-year net loss fell to $52...
Intercept Pharma (ICPT): Q4 GAAP EPS of -$1.58 misses by $0.09.Revenue of $83.2M (+16.4% Y/Y) misses by $1.69M.Intercept provides initial 2021 Worldwide Ocaliva Net Sales Guidance of $325 million to $355 million and Non-GAAP Adjusted Operating Expense Guidance of $380 to $410 million.Shares +...
Worldwide Ocaliva ® net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior year Intercept provides initial 2021 Worldwide Ocaliva Net Sales Guidance of $325 million to $355 millio...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...